Recently, one of our readers reached out with a very practical question about digitalising QA: they were choosing between Kneat and ValGenesis as validated software
Four out of five MedTech teams we speak to act as if their eQMS makes them audit‑ready. Then the first FDA inspection hits, and that assumption doesn’t hold up
Two systems. One critical mistake. And the question most GxP leaders get wrong: where does your eQMS stop—and your data integrity risk begin?
With implementation due on 28 April 2026, the MHRA’s ICH GCP E6(R3) rollout is turning GCP compliance into an immediate operational issue for UK sponsors
Drug discovery timelines are still measured in years—despite billions invested in AI.
So which platforms are genuinely accelerating R&D—and which are just adding another layer of complexity?
We analysed BenevolentAI, Atomwise, and Insilico Medicine to find out.
I’ve spent 20+ years validating static systems.
Now I’m watching real-time analytics platforms make decisions faster than we can explain, justify, or defend them.
That should make every GxP leader pause
